Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CEFAZODIAL
2023-506734-73-00Phase 4Completed
- Sponsor
- CHRU Tours
- Start
- Oct 2023
- Modality
- Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of cefazolin in bacterial disease, Staphylococcus aureus infection, Gram-positive bacteremia (GPB) and 1 more, sponsored by CHRU Tours. Started Oct 2023; status: completed.
02
Drugs
cefazolin
03
Conditions
bacterial diseaseStaphylococcus aureus infectionGram-positive bacteremia (GPB)Infection
Beyond the preview
Go deeper on 2023-506734-73-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506734-73-00.